Learn From the Experts About
Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology
Learn about the immune system and immune checkpoint targets, as well as everything the oncology AP needs to know about managing immune-related adverse events.
Select a Location
Philadelphia, PA • April 14, 2018
New York, NY • April 28, 2018
Tampa, FL • May 5, 2018
Dallas, TX • September 15, 2018
Orange County, CA • October 6, 2018
Upon completion of this activity, participants will be able to:
- Differentiate between early and late adverse effects associated with immunotherapeutic agents.
- Recognize the differences between the immunotherapeutic agents and of chemotherapeutic agents: mechanisms of action, adverse effects, and toxicity management.
- Summarize data on currently available immunotherapeutic agents as they relate to durable treatment responses.
- Explain the utility of biomarker testing in selecting patients for immunotherapy and in predicting clinical outcomes.